SCHEMBL3713112

SCHEMBL3713112

CS(=O)(=O)OCc1c(F)cc(C(=O)O)cc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
MAPK1 P28482 2/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
HCAR1 Q9BXC0 3/20 0.38
TTR P02766 1/20 0.36
CA12 O43570 3/20 0.35
CA1 P00915 3/20 0.35
CA2 P00918 3/20 0.35
CA7 P43166 3/20 0.35
CA9 Q16790 3/20 0.35
CA14 Q9ULX7 3/20 0.35
LCK P06239 1/20 0.35
FYN P06241 1/20 0.35
PTGS2 P35354 1/20 0.35
CA3 P07451 2/20 0.34
CA4 P22748 2/20 0.34
CA6 P23280 2/20 0.34
CA5A P35218 2/20 0.34
CA5B Q9Y2D0 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL602329 0.80 CA12 (0.38) CA12CA1CA2CA9CA14
SCHEMBL856447 0.77 APLNR (0.32) LMNAKDM4EALDH1A1
SCHEMBL18464343 0.77 ESR1 (0.54) LMNAMAPK1SMN1; SMN2
SCHEMBL31385498 0.76 MRGPRX4 (0.52) LMNAMAPK1HTTRAB9ATTR
SCHEMBL17197208 0.75 NR1I2 (0.33)
SCHEMBL2800941 0.73 EPAS1 (0.36)
SCHEMBL4129553 0.72 LMNA (0.44) LMNAMAPK1HTTRAB9AHCAR1
SCHEMBL602189 0.72 STAT3 (0.37) LMNAMAPK1HTTCA12CA1
SCHEMBL15164140 0.72 KCNQ2 (0.35) LMNAKDM4EALDH1A1
SCHEMBL15592425 0.72 MAPK1 (0.41) LMNAMAPK1HTTRAB9AHCAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2396304-A1 TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY Exelixis, Inc. (US) 2011-12-21 EP disclosed
WO-2010093845-A1 TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY EXELIXIS, INC. (US) 2010-08-19 WO disclosed